vs
Side-by-side financial comparison of SOLESENCE, INC. (SLSN) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $12.5M, roughly 1.0× SOLESENCE, INC.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 1.3%, a 249.4% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -0.7%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 12.5%).
SLSN vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $12.6M |
| Net Profit | $163.0K | $31.5M |
| Gross Margin | 27.5% | — |
| Operating Margin | 1.5% | — |
| Net Margin | 1.3% | 250.7% |
| Revenue YoY | -0.7% | 24080.8% |
| Net Profit YoY | 129.2% | 250.9% |
| EPS (diluted) | $0.00 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | $12.6M | ||
| Q3 25 | $14.6M | $0 | ||
| Q2 25 | $20.4M | $0 | ||
| Q1 25 | $14.6M | $12.0K | ||
| Q4 24 | $12.6M | $52.0K | ||
| Q3 24 | $16.9M | $65.0K | ||
| Q2 24 | $13.0M | $114.0K | ||
| Q1 24 | $9.9M | $140.0K |
| Q4 25 | $163.0K | $31.5M | ||
| Q3 25 | $-1.1M | $-7.4M | ||
| Q2 25 | $2.7M | $-1.7M | ||
| Q1 25 | $80.0K | $-13.9M | ||
| Q4 24 | $-559.0K | — | ||
| Q3 24 | $3.0M | $-17.1M | ||
| Q2 24 | $856.0K | $-17.9M | ||
| Q1 24 | $893.0K | $-12.7M |
| Q4 25 | 27.5% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 28.9% | — | ||
| Q1 25 | 23.1% | — | ||
| Q4 24 | 22.0% | — | ||
| Q3 24 | 36.2% | — | ||
| Q2 24 | 28.7% | — | ||
| Q1 24 | 36.3% | — |
| Q4 25 | 1.5% | — | ||
| Q3 25 | -5.4% | — | ||
| Q2 25 | 9.4% | — | ||
| Q1 25 | 1.8% | -122758.3% | ||
| Q4 24 | -1.8% | — | ||
| Q3 24 | 19.0% | -28604.6% | ||
| Q2 24 | 8.0% | -16720.2% | ||
| Q1 24 | 11.3% | -9987.1% |
| Q4 25 | 1.3% | 250.7% | ||
| Q3 25 | -7.7% | — | ||
| Q2 25 | 13.1% | — | ||
| Q1 25 | 0.5% | -115550.0% | ||
| Q4 24 | -4.4% | — | ||
| Q3 24 | 18.1% | -26380.0% | ||
| Q2 24 | 6.6% | -15668.4% | ||
| Q1 24 | 9.0% | -9049.3% |
| Q4 25 | $0.00 | $0.56 | ||
| Q3 25 | $-0.02 | $-0.13 | ||
| Q2 25 | $0.04 | $-0.03 | ||
| Q1 25 | $0.00 | $-0.25 | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.04 | $-0.32 | ||
| Q2 24 | $0.01 | $-0.33 | ||
| Q1 24 | $0.02 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.6M | $59.0M |
| Total Assets | $50.1M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | $40.3M | ||
| Q3 25 | $429.0K | $48.6M | ||
| Q2 25 | $4.1M | $31.2M | ||
| Q1 25 | $1.8M | $48.9M | ||
| Q4 24 | $1.4M | $52.9M | ||
| Q3 24 | $2.9M | $76.3M | ||
| Q2 24 | $2.4M | $63.5M | ||
| Q1 24 | $2.0M | $82.3M |
| Q4 25 | $17.6M | $59.0M | ||
| Q3 25 | $17.2M | $26.5M | ||
| Q2 25 | $18.2M | $32.8M | ||
| Q1 25 | $15.2M | $33.8M | ||
| Q4 24 | $14.9M | $46.1M | ||
| Q3 24 | $15.2M | $65.5M | ||
| Q2 24 | $11.9M | $80.5M | ||
| Q1 24 | $5.0M | $96.2M |
| Q4 25 | $50.1M | $68.9M | ||
| Q3 25 | $54.0M | $54.2M | ||
| Q2 25 | $60.0M | $62.1M | ||
| Q1 25 | $57.0M | $77.7M | ||
| Q4 24 | $50.0M | $110.5M | ||
| Q3 24 | $48.0M | $135.2M | ||
| Q2 24 | $40.8M | $149.9M | ||
| Q1 24 | $38.5M | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 11.16× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-8.4M | ||
| Q3 25 | $-2.5M | $17.4M | ||
| Q2 25 | $-654.0K | $-17.7M | ||
| Q1 25 | $-7.2M | $-4.0M | ||
| Q4 24 | $2.2M | $-23.4M | ||
| Q3 24 | $4.2M | $12.8M | ||
| Q2 24 | $-565.0K | $-18.7M | ||
| Q1 24 | $-3.9M | $5.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-404.0K | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $-1.0M | — | ||
| Q1 24 | $-3.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.2% | — | ||
| Q3 24 | 16.6% | — | ||
| Q2 24 | -8.0% | — | ||
| Q1 24 | -39.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.6% | — | ||
| Q3 24 | 8.3% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | 11.16× | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.25× | — | ||
| Q1 25 | -90.26× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | -0.66× | — | ||
| Q1 24 | -4.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
